5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-20-pyrazolo[4,3-d]pyrimidin-7-one | 147676-53-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-20-pyrazolo[4,3-d]pyrimidin-7-one
• 英文别名: 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one；5-(2-ethoxy-5-(2-(4-morpholino)acetyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one；5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one；Morpholinoacetildenafil；5-[2-ethoxy-5-(2-morpholin-4-ylacetyl)phenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
• CAS: 147676-53-7
• 化学式: C₂₃H₂₉N₅O₄
• 分子量: 439.514
• InChiKey: AANJEOKXWMXQIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  98
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Substituted triazole derivatives as oxytocin antagonists
  申请人：Brown Daniel Alan

  公开号：US20060160786A1

  公开（公告）日：2006-07-20

  The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.

  本发明涉及公式（I）的取代三唑化合物，其用途，制备方法以及含有该化合物的组合物。这些抑制剂在包括性功能障碍在内的各种治疗领域具有用途。
• N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
  申请人：——

  公开号：US20030105132A1

  公开（公告）日：2003-06-05

  The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R 1 is optionally substituted C 1-6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C 1-6 alkoxy, —NR 2 R 3 or —NR 4 SO 2 R 5 ; X is the linkage —(CH 2 ) n — or —(CH 2 ) q —O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C 1-4 alkoxy; hydroxy; hydroxy(C 1-3 alkyl); C 3-7 cycloalkyl; carbocyclyl; heterocyclyl; or by C 1-4 alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R 8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5 - or 6 -membered carbocyclic or heterocyclyic ring. 1

  该发明涉及用于治疗性功能障碍的化合物(I)的公式，其中R1是可选择取代的C1-6烷基，可选择取代的碳环烷基，可选择取代的杂环烷基，氢，C1-6烷氧基，—NR2R3或—NR4SO2R5；X是连接基—(CH2)n—或—( )q—O—（其中Y连接到氧原子）；其中连接基X中的一个或多个氢原子可以独立地被C1-4烷氧基，羟基，羟基(C1-3烷基)，C3-7环烷基，碳环烷基，杂环烷基或可选择取代的一个或多个氟或苯基的C1-4烷基替代；n为3、4、5、6或7；q为2、3、4、5或6；Y为苯基或吡啶基，每个基都可以被取代；或相邻碳原子上的两个R8基连同相互连接的碳原子可以形成一个可选择取代的5-或6-成员碳环或杂环环。
• Pharmaceutically active compounds
  申请人：Calabrese Antony Andrew

  公开号：US20050176772A1

  公开（公告）日：2005-08-11

  The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

  本发明涉及一类通式（I）所示的黑素皮质素MCR4激动剂，其中R1、R2、R3、R4和R5如本文所定义，特别涉及选择性MCR4激动剂化合物，它们在医学上的应用，含有它们的组合物，用于它们制备的工艺以及用于这些工艺的中间体。
• Compounds Useful In Therapy
  申请人：Gibson Karl Richard

  公开号：US20080096950A1

  公开（公告）日：2008-04-24

  Compounds of Formula (I): and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, are useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

  化合物的化学式（I）： 以及所述化合物及其盐、溶剂化合物（包括水合物）和盐、或所述化合物的前药，或所述前药的药学上可接受的盐或溶剂化合物，其中取代基如本文所定义，可用于治疗，例如它们可能对治疗孕激素介导的疾病如子宫内膜异位症、子宫肌瘤（平滑肌瘤）、月经过多、子宫腺肌病、原发性和继发性痛经（包括性交疼痛、排便疼痛和慢性盆腔疼痛症状）或慢性盆腔疼痛综合症等方面具有用处。
• Compounds useful in therapy
  申请人：Bradley Anthony Paul

  公开号：US20070105909A1

  公开（公告）日：2007-05-10

  Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R 1 and R 3 independently represent H, C 1-6 alkyl, C 3-8 cycloalkyl, or halogen; R 2 represents C 1-6 alkyl, CF 3 or aryl; a represents 1 or 2; R 4 , R 5 , R 7 and R 8 independently represent H, C 1-6 alkyl, C 1-6 alkyloxy, CN or halogen, or R 4 and R 5 , or R 7 and R 8 , together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH 2 or O; R 6 represents H, CN or halo provided that, when X represents N, R 6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

  式(I)的化合物，或其药学上可接受的衍生物，其中R1和R3独立地代表H、C1-6烷基、C3-8环烷基或卤素；R2代表C1-6烷基、CF3或芳基；a代表1或2；R4、R5、R7和R8独立地代表H、C1-6烷基、C1-6烷氧基、CN或卤素，或R4和R5，或R7和R8，与它们连接的环一起形成芳基或杂环融合环系统；X代表C或N；Y代表CH2或O；R6代表H、CN或卤素，但当X代表N时，R6不存在。这些化合物可用于治疗子宫内膜异位症、子宫肌瘤（平滑肌瘤）、月经过多、子宫腺肌病、原发性和继发性痛经（包括性交疼痛、性交困难和慢性盆腔疼痛症状）或慢性盆腔疼痛综合征。